Results 61 to 70 of about 10,701 (213)

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

How to become a licensed psilocybin testing laboratory in Oregon. Spanish

, 2023
Title from PDF caption (viewed on February 16, 2023).This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core  

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

How to become a licensed psilocybin service center in Oregon. Spanish

, 2023
Title from PDF caption (viewed on February 24, 2023).This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core  

The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial

Addiction, EarlyView.
Abstract Background and aims Ketamine assisted psychotherapy is a promising new treatment for alcohol use disorder (AUD). The psychoactive effects of repeated intravenous (IV) ketamine infusions in people with AUD and their mechanistic role in treating AUD are largely unknown.
Cassie Bloy, Ananya Sarma, Bethan Marsh, Lorna Hardy, Meryem Grabski, Merve Mollaahmetoglu, Joshua Shotton, Shamhethan Bhaskaran, Anne Lingford‐Hughes, H. Val Curran, Celia Morgan, Will Lawn   +11 more
wiley   +1 more source

How to become a licensed psilocybin services facilitator in Oregon. Spanish

, 2023
Title from PDF caption (viewed on February 16, 2023).This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core  

Unlocking ‘stuckness’ and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic‐assisted therapy for substance use and mental health problems

Addiction, EarlyView.
Abstract Background and aims Australia recently down‐scheduled and authorised psychedelic‐assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness.
Sarah J. Catchlove, Katrin Oliver, Michael Savic, Shalini Arunogiri   +3 more
wiley   +1 more source

Assessing potential of psilocybin for depressive disorders

, 2023
There has been increasing interest in the role psilocybin may play in the treatment of depressive disorders. Several clinical trials have shown psilocybin to have efficacy in reducing symptoms of depression.
Scott T. Aaronson (17326700), Matthew W. Johnson (8341866), Zofia Kozak (17326697)   +2 more
core   +1 more source

Psychological change processes in alcohol use disorder: A qualitative study of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) with cognitive behavioural therapy

Addiction, EarlyView.
Abstract Background and aims This study qualitatively explored psychological change processes as described by participants and therapists within a phase 2a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a single dose of intranasal 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT; BPL‐003) administered alongside psychological
Mathieu Seynaeve, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, James J. Rucker, Anthony Cleare, John Marsden   +6 more
wiley   +1 more source

Psilocybin reduces low frequency oscillatory power and neuronal phase-locking in the anterior cingulate cortex of awake rodents

Scientific Reports, 2022
Psilocybin is a hallucinogenic compound that is showing promise in the ability to treat neurological conditions such as depression and post-traumatic stress disorder.
Caroline T. Golden, Paul Chadderton
doaj   +1 more source